Depression Clinical Trial
Official title:
Neurophysiologic Predictors of Outcome With rTMS Treatment of Major Depressive Disorder
Transcranial magnetic stimulation (TMS) therapy has proven to lead to symptom improvement in many individuals with major depressive disorder (MDD), yet there is heterogeneity in outcome, with some patients showing robust remission and other showing minimal symptom change. Identifying which individuals are likely to benefit from TMS therapy early in the course of treatment would support continued treatment for those predicted to do well, and consideration of alternative treatments for others individuals. This study will test specific hypotheses about the relationships between early neurophysiologic changes and later clinical outcome with TMS treatment.
A critical challenge in the management of major depressive disorder (MDD) is the selection
of treatment for each individual patient. Although treatments with depression can restore
people's lives, with any treatment modality there are some individuals who do not achieve
complete remission of symptoms, whether the intervention is pharmacological, psychological,
or somatic. While predictors for some treatments have been proposed for groups of patients,
the translation of these predictors to individualized patient care has remained elusive. In
an analysis of data from the NCT 00104611 multi-site, randomized, sham-controlled trial of
TMS, it was found that a larger number of prior treatment failures, longer duration of the
current episode, and the presence of comorbid anxiety were individual patient
characteristics associated with poorer acute outcomes with TMS treatment in the randomized
period (Lisanby et al., in press). This publication did not report standard predictor
metrics (e.g., sensitivity, specificity, positive- or negative-predictive accuracy, ROC
curves), so it is difficult to assess the value of these clinical factors in treatment
planning for individual patients. A predictor that could distinguish between individuals
likely to remit with TMS versus those likely to need a different intervention would be of
great use to clinicians and patients in making treatment decisions.
Our prior work (Cook et al., 2001, 2002, 2005; Leuchter et al. 2002) has studied a new
physiologic biomarker of response to SSRI and mixed-action antidepressants. The EEG-based
cordance biomarker can detect the physiologic effects of successful antidepressant treatment
at 48 hours, 1 week, and 2 weeks of treatment; in contrast, symptom differences between
responders and non-responders did not separate until 4 weeks of treatment in our
placebo-controlled trials. Additionally, the magnitude of early physiologic change was
associated with the completeness of clinical response. Our biomarker has been independently
studied and our findings replicated (Kopecek et al., 2006; Bareš et al., 2007, 2008). The
cordance biomarker can be considered as a leading indicator or predictor of treatment
outcome. As a non-invasive probe of brain physiology, it may detect early neurophysiologic
changes associated with accelerated clinical response from TMS.
More recent work with a related EEG-based measure, the Antidepressant Treatment Response
Index (ATR) has led to a simplified monitoring system; a physician can record
clinically-useful data from a 15-minute in-office procedure with electrodes located on the
forehead and ears (Leuchter et al., in submission). The ATR uses physiologic data collected
prior to treatment and after one week of exposure, and was shown to be predictive of outcome
with antidepressant medication. We are able to assess both cordance and ATR measures with
EEG measurements made prior to treatment and after 5 treatment sessions with TMS to evaluate
the predictive properties of both metrics.
On a related issue, some of the variation in outcome may be related to treatment factors.
Quantitative models and direct in vivo measurements (Wagner et al, 2004, 2008) indicate that
the electrical currents induced by TMS are predominantly confined to a brain region directly
under the treatment coil. The procedure for positioning the coil over the cortical target is
described in the NeuroStar TMS System User Manual (volume 2, sections 6 and 7) and involves
first determining a location where stimulation leads to a contraction of the abductor
policis brevis muscle (visualized with a thumb twitch on the right hand) and then
positioning the coil 5.5 cm anterior to that position along the left Superior Oblique Angle
line. While this target can be located with good reproducibility and was associated with
therapeutic outcome in the NCT trial, it is not clear that this positions the coil over the
best target within the DLPFC for all patients. Indeed, individual differences in gyral
anatomy and in gross brain size both add variability to the specific neuroanatomic region
being stimulated, and this may impact treatment efficiency.
Exposure to even a brief train of TMS pulses can elicit an acute physiologic change (cf
Siebner and Rothwell, 2003), and so a test procedure can be performed that will assess the
distance from the standard treatment position to the point eliciting a maximal acute
physiologic response. We propose a 9-locus mapping procedure, involving the assessment of
changes in brain activity from stimulation at locations including and around the standard
treatment target. The nine locations will be the usual treatment location and 8 other
points, 1.5 and 3.0 cm anterior, posterior, rostral, and caudal of the primary target. Test
stimulation will be for 15 seconds (=150 pulses @ 10 Hz) at each location, followed by 5
minutes of continuous EEG recording to examine acute changes in regional brain activity in
response to a brief stimulation exposure. All therapeutic stimulations will take place in
the standard location, and we will be able to evaluate what proportion of variance in
clinical outcome is explained by distance from the location of maximal acute physiologic
response.
Based on these previous studies, we propose to assess patients during treatment with TMS,
using clinical symptom ratings and brain physiology with EEG.
;
Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A |